Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis (Spine1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03100032
Recruitment Status : Active, not recruiting
First Posted : April 4, 2017
Last Update Posted : March 27, 2019
Sponsor:
Information provided by (Responsible Party):
Novadip Biosciences

Tracking Information
First Submitted Date  ICMJE February 8, 2017
First Posted Date  ICMJE April 4, 2017
Last Update Posted Date March 27, 2019
Study Start Date  ICMJE January 2017
Estimated Primary Completion Date January 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 25, 2019)
  • NVD-001 (nocc AEs) [ Time Frame: 12 months ]
    Number of Adverse Events (AEs) severity, relatedness to the product or procedure, required action and outcome, up to 12 months post-surgery
  • NVD-001 (npat AEs) [ Time Frame: 12 months ]
    Number of participants presenting Adverse Events (AEs).
  • NVD-001 (nocc SAEs) [ Time Frame: 24 months ]
    Number of serious Adverse Events (SAEs), severity, relatedness to the product or procedure, required action and outcome.
  • NVD-001 (npatSAEs) [ Time Frame: 24 months ]
    Number of participants presenting Serious Adverse Events (AEs).
  • NVD-001 (nocc AESI) [ Time Frame: 24 months ]
    Number of Adverse Events of Special Interest (AESI) using lumbar spine CT and radiographic images.
  • NVD-001 (npat AESI) [ Time Frame: 24 months ]
    Number of participants with Adverse Events of Special Interest (AESI) using lumbar spine CT and radiographic images.
  • NVD-001 (npat Safety X-rays) [ Time Frame: 24 months ]
    Number of participants with appearance or absence of calcification/ ossification and ectopic bone formation in comparison with preoperative, as determined by chest X-rays.
  • NVD-001 (npat Safety Post-Op) [ Time Frame: 1 month ]
    Number of participants with occurrence or absence of surgical intervention-related safety parameters such as infection and peri- and post-operative blood loss volume
Original Primary Outcome Measures  ICMJE
 (submitted: March 28, 2017)
  • NVD-001 (nocc AEs) [ Time Frame: 24 months ]
    Number of Adverse Events (AEs) severity, relatedness to the product or procedure, required action and outcome.
  • NVD-001 (npat AEs) [ Time Frame: 24 months ]
    Number of participants presenting Adverse Events (AEs).
  • NVD-001 (nocc SAEs) [ Time Frame: 24 months ]
    Number of serious Adverse Events (SAEs), severity, relatedness to the product or procedure, required action and outcome.
  • NVD-001 (npatSAEs) [ Time Frame: 24 months ]
    Number of participants presenting Serious Adverse Rvents (AEs).
  • NVD-001 (nocc AESI) [ Time Frame: 24 months ]
    Number of Adverse Events of Special Interest (AESI) using lumbar spine CT and radiographic images.
  • NVD-001 (npat AESI) [ Time Frame: 24 months ]
    Number of participants with Adverse Events of Special Interest (AESI) using lumbar spine CT and radiographic images.
  • NVD-001 (npat Safety X-rays) [ Time Frame: 24 months ]
    Number of participants with appearance or absence of calcification/ ossification and ectopic bone formation in comparison with preoperative, as determined by chest X-rays.
  • NVD-001 (npat Safety Post-Op) [ Time Frame: 1 month ]
    Number of participants with occurrence or absence of surgical intervention-related safety parameters such as infection and peri- and post-operative blood loss volume
Change History Complete list of historical versions of study NCT03100032 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 25, 2019)
  • NVD-001 (LSF) [ Time Frame: 24 months ]
    Lumbar Spine Fusion progression and non-fusion assessed by serial CT-Scans images of lumbar spine post-surgery and lumbar spine static and dynamic radiographic images.
  • NVD-001 (ODI) [ Time Frame: 24 months ]
    Functional disability by means of Oswestry Disability Index (ODI).
  • NVD-001 (BPI) [ Time Frame: 24 months ]
    Pain by means of Brief Pain Inventory (BPI).
  • NVD-001 (OTE) [ Time Frame: 24 months ]
    Overall treatment effect using OTE scale.
  • NVD-001 (QoL) [ Time Frame: 24 months ]
    Quality of life (QoL) by means of patient's questionnaire EuroQoL 5 Dimensions post-surgery.
  • NVD-001 (timeSurgery) [ Time Frame: 1 day ]
    Surgical duration.
  • NVD-001 (stayPostOp) [ Time Frame: 7 days ]
    Duration of postoperative hospital stay.
  • NVD-001 (subsequentSurgery) [ Time Frame: 24 months ]
    Description of subsequent surgical interventions (revision, removal, reoperation and supplemental fixation).
Original Secondary Outcome Measures  ICMJE
 (submitted: March 28, 2017)
  • NVD-001 (LSF) [ Time Frame: 24 months ]
    Lumbar Spine Fusion progression and non-fusion assessed by serial CT-Scans images of lumbar spine post-surgery and lumbar spine static and dynamic radiographic images.
  • NVD-001 (ODI) [ Time Frame: 24 months ]
    Functional disability by means of Oswestry Disability Index (ODI).
  • NVD-001 (BPI) [ Time Frame: 24 months ]
    Pain by means of Brief Pain Inventory (BPI).
  • NVD-001 (OTE) [ Time Frame: 24 months ]
    Overall treatment effect using OTE scale.
  • NVD-001 (QoL) [ Time Frame: 24 months ]
    Quality of life (QoL) by means of patient's questionnaire EuroQoL 5 Dimensions post-surgery.
  • NVD-001 (timeSurgery) [ Time Frame: 24 months ]
    Surgical time.
  • NVD-001 (stayPostOp) [ Time Frame: 24 months ]
    Duration of postoperative hospital stay.
  • NVD-001 (subsequentSurgery) [ Time Frame: 24 months ]
    Description of subsequent surgical interventions (revision, removal, reoperation and supplemental fixation).
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis
Official Title  ICMJE A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)
Brief Summary A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by interbody fusion (L1 - S1).
Detailed Description

This is a prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by interbody fusion of one vertebral segment (L1-S1). The study consists of a 12-month initialfollow-up period post-surgery and a subsequent 12-month long term follow-up.

NVD-001 is an autologous cellular medicinal product obtained by culture of adipose tissue (liposuction) leading to osteogenic cells after ex vivo isolation, expansion and differentiation of pluripotent adipose-tissue stem cells (ASC), and combination with an allogeneic fully demineralised bone matrix into a 3D bone implant.

Patients diagnosed with symptomatic degenerative spondylolisthesis grade I or II with an indication for spinal fusion of one vertebral segment (L1-S1) who sign informed consent and are eligible will be randomised either to the experimental group (surgical intervention for spinal lumbar interbody fusion with NVD-001) or to the control group (commonly used surgical intervention for spinal lumbar interbody fusion (TLIF, PLIF, minimally invasive or open approach) with one or two PEEK cage(s) filled and surrounded by locally harvested autologous cancellous bone (laminectomy).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Spondylolisthesis
Intervention  ICMJE
  • Biological: NVD-001
    At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
  • Procedure: Standard of Care
    At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
Study Arms  ICMJE
  • Experimental: NVD-001
    Autologous osteogenic cells in ECM with DBM
    Intervention: Biological: NVD-001
  • Active Comparator: Standard of Care
    Best standard of care in surgical practice
    Intervention: Procedure: Standard of Care
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: March 25, 2019)
48
Original Estimated Enrollment  ICMJE
 (submitted: March 28, 2017)
36
Estimated Study Completion Date  ICMJE January 2021
Estimated Primary Completion Date January 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Any subject meeting all of the following inclusion criteria and verified by the Investigator during the screening period:

  • Subject has understood and accepted to participate in the study according to all study procedures by signing the approved informed consent.
  • Male or female subjects aged >18 and is skeletally mature (epiphyses closed).
  • Subject has clinically important pain or neurological symptoms with or without claudication due to symptomatic degenerative spondylolisthesis grade I or II (Meyerding Classification).
  • Conservative treatment of disease has failed for at least 3 months since diagnosis. (ISASS 2011)
  • Subject has a preoperative ODI score >30.
  • Subject has an indication for spinal fusion of one vertebral segment (L1-S1) due to symptomatic degenerative spondylolisthesis grade I or II diagnosed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI) and/or dynamic radiography.
  • Subject is suitable for surgical operation and incorporation of the PEEK cage(s) by transforaminal lumbar interbody fusion (TLIF) or posterior lumbar intervertebral fusion (PLIF) by minimally invasive or open approach in one mobile segment (L1- S1) with bilateral rigid fixation. No posterolateral lumbar fusion (PLF) technique is allowed.
  • Subject is, in the Investigator's opinion, psychosocially, mentally and physically able to fully comply with this protocol, including the postoperative regimen and follow-up visits.
  • At screening, local laboratory safety test results are clinically acceptable and serology results for HIV, HBV, HCV, HTLV I/II and syphilis are in accordance with country specific requirements for donation of Human Body Material. At time of adipose tissue collection, central laboratory serology and molecular test panel for HIV, HBV, HCV, HTLV I/II and syphilis must be in accordance with Belgian specific requirements for release of Human Body Material.
  • Women of childbearing potential (WOCBP) including peri-menopausal women who have had a menstrual period within 1 year prior to surgery have to have a negative pregnancy test. Results have to be available and negative for the patient to be entered in the study.
  • WOCBP have to use an effective method of birth control 2 months prior to study entry or to surgical intervention date and throughout the study duration (defined as a method which results in a failure rate of less than 1% per year) such as:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    • Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomised partner (provided that partner is the sole sexual partner of the trial participant and that the surgical success of vasectomy has been confirmed)
    • Sexual abstinence For each case of delayed menstrual period, confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to WOCBP with infrequent or irregular menstrual cycles. In case a urine pregnancy test is positive, a confirmatory blood pregnancy test is obligatory.

Exclusion Criteria:

Any subject meeting any of the following exclusion criteria verified by the Investigator during the screening period will be excluded from enrolment into the study.

  • Subject has known history of hypersensitivity or anaphylactic reaction to PEEK.
  • Due to medical or other reasons spine fusion cannot be delayed for up to 6 months.
  • Indications for spinal fusion other than symptomatic degenerative spondylolisthesis grade I and II (Meyerding Classification).
  • Subject displays drug or alcohol dependence, serious current illness, mental illness or extenuating circumstance or any other factors which, in the opinion of the Investigator, will interfere with study conduct or interpretation of the results.
  • Subject has documented metabolic disease such as but not limited to severe osteoporosis, osteogenesis imperfect, or osteomalacia.
  • Subject with poorly controlled diabetes mellitus as assessed by glycohaemoglobin (HbA1c) > 8% (at least 2 values per year for last 2 years)
  • Subject is underweight, i.e. body mass index (BMI) ≤18.5 or has a BMI of ≥40, or ≥35 and experiencing obesity-related health conditions, such as high blood pressure or diabetes at V0a.
  • Overt or active local or systemic infection, including latent infection around (area of) the future surgical implant site.
  • Subject has a history of previously attempted spinal fusion at the same level, or spine level immediately adjacent to the level to be operated on in this study. Decompressive surgery alone (laminectomy) is not an exclusion criterion.
  • Subject is on a transplant list or having received a solid organ transplant at any point in the past.
  • Pregnant or breast-feeding woman.
  • Involved in or planning to engage in litigation related health problems.
  • Subject is a prisoner.
  • Subject had an acute fracture of the spine within 6 months prior V0a in the study.
  • Subject is known to require additional surgery to the lumbar spinal region within the next 2 years after enrolment in the study.
  • Subject is currently taking chronically any medications that might affect bone metabolism or the quality of bone formation such as but not limited to bisphosphonates, steroids, methotrexate, anticoagulant therapies, immunosuppressants or immunotherapy.
  • Subject is currently using an electrical bone growth stimulator
  • Subject is positive for human immunodeficiency virus (HIV) 1 or 2, hepatitis B (HBsAg or PCR positive) or C, human T-cell lymphotropic virus (HTLV) 1 or 2, or syphilis at screening (V0a).
  • Subject was exposed to any experimental therapy with another investigational drug within 60 days prior to screening or enrolment in any concurrent study that may confound the results of this study.
  • Subject previously received a cellular therapy (at any point in time).
  • Subject was exposed to therapy for a malignancy or pre-malignant entity, and not confirmed disease-free for 5 years or more.
  • Any clinically relevant chronic disease associated with renal or hepatic insufficiency or any chronic disease of such severity that surgery could be detrimental to the survival of the patient.
  • Any other illness which might reduce life expectancy to less than 2 years from screening.
  • Subject is on chronic immunosuppressive therapy (immunosuppressants/immunotherapy) due to inflammatory or systemic disease.
  • Subject has an active inflammatory systemic autoimmune disease that could interfere with bone metabolism such as but not limited to rheumatoid arthritis, ankylosing spondylarthritis, inflammatory bowel disease, systemic lupus erythematosus or thyroid diseases.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Czechia,   Poland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03100032
Other Study ID Numbers  ICMJE NVD-CLN01
2016-002642-23 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Upon study completion, coded data, in EudraPharm database (http://www.eudrapharm.eu)
Responsible Party Novadip Biosciences
Study Sponsor  ICMJE Novadip Biosciences
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Béatrice De Vos, MD, PhD Novadip Biosciences
Principal Investigator: Christian Raftopoulos, MD, PhD Saint-Luc University Hospital, Department of Neurosurgery
PRS Account Novadip Biosciences
Verification Date June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP